Millennium Pharmaceuticals, Inc. (MLNM)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
3044	135	0	MLNM

Emcee: icanpickem	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
2919	Third Rock Ventures Debuts with $378 Million Fund in Life Sciences Friday Septem	Icebrg	-	9/14/2007
2918	[ad-MDA7 + velcade versus tumors -- from the "velcade works with almost eve	tuck	-	9/12/2007
2917	[Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis] >>	tuck	-	9/11/2007
2916	[Alternating Bortezomib and Dexamethasone As Induction Regimen for Multiple Myel	tuck	-	9/6/2007
2915	Reversal of acute renal failure by bortezomib-based chemotherapy in patients wit	Icebrg	-	9/5/2007
2914	Use of bortezomib in the management of chronic graft-versus-host disease among m	Icebrg	-	9/5/2007
2913	Inhibition of Akt induces significant downregulation of survivin and cytotoxicit	Icebrg	-	9/4/2007
2912	Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and t	Icebrg	-	9/4/2007
2911	The ever-so-diligent Dr. West has recently been discussing thr ude of Velcade in	Icebrg	-	9/3/2007
2910	Effects of the Proteasome Inhibitor Bortezomib on Gene Expression Profiles of Pa	Icebrg	-	8/31/2007
2909	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or R	Icebrg	-	8/31/2007
2908	[Bortezomib as induction therapy in MM ] >>Curr Treat Options Oncol. 2007	tuck	-	8/24/2007
2907	[Bortezomib alone and in combination with cisplatin or docetaxel in head and nec	tuck	-	8/21/2007
2906	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-t	Icebrg	-	8/14/2007
2905	The new firm in town Mark Levin, the founder and long-time chief executive of M	Icebrg	-	8/13/2007
2904	Unfortunately, the Cowen analyst fails to understand that myeloma is a disease f	Mike K	-	8/8/2007
2903	NEW YORK (AP) -- A Cowen and Co. analyst initiated or revised coverage on severa	Icebrg	-	8/8/2007
2902	Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With	Icebrg	-	8/8/2007
2901	Belinostat in combination with Velcade® (bortezomib) for Injection against	Icebrg	-	8/7/2007
2900	KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma ByDon	Icebrg	-	8/3/2007
2899	First clinical experience with simvastatin to overcome drug resistance in refrac	Icebrg	-	7/31/2007
2898	[A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.] >>Oncogene. 2	tuck	-	7/27/2007
2897	[The combination of cyclophosphamide, velcade and dexamethasone induces high res	tuck	-	7/26/2007
2896	Morgan Stanley - not too happy. Based on IMS, Velcade sales are up 5 % largely	Icebrg	-	7/21/2007
2895	Public release date: 19-Jul-2007 Contact: Greg Lester lester@aacr.org 267-646-0	Ian@SI	-	7/19/2007

Go to reply# or date (mm/dd/yy):